CA2001673C - Pharmaceutical composition containing piroxicam - Google Patents

Pharmaceutical composition containing piroxicam

Info

Publication number
CA2001673C
CA2001673C CA002001673A CA2001673A CA2001673C CA 2001673 C CA2001673 C CA 2001673C CA 002001673 A CA002001673 A CA 002001673A CA 2001673 A CA2001673 A CA 2001673A CA 2001673 C CA2001673 C CA 2001673C
Authority
CA
Canada
Prior art keywords
mass
parts
pharmaceutical composition
process according
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002001673A
Other languages
English (en)
French (fr)
Other versions
CA2001673A1 (en
Inventor
Pal Fekete
Denes Bezzegh
Istvan Simonyi
Biborka Maroshelyi
Katalin Zukovics
Janos Tombor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Publication of CA2001673A1 publication Critical patent/CA2001673A1/en
Application granted granted Critical
Publication of CA2001673C publication Critical patent/CA2001673C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002001673A 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam Expired - Fee Related CA2001673C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU5621/88 1988-10-28
HU885621A HU200926B (en) 1988-10-28 1988-10-28 Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Publications (2)

Publication Number Publication Date
CA2001673A1 CA2001673A1 (en) 1990-04-28
CA2001673C true CA2001673C (en) 1996-08-27

Family

ID=10970484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002001673A Expired - Fee Related CA2001673C (en) 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam

Country Status (9)

Country Link
JP (1) JPH02172918A (ja)
AT (1) AT399277B (ja)
CA (1) CA2001673C (ja)
DE (1) DE3936112C2 (ja)
FR (1) FR2638357B1 (ja)
GB (1) GB2224207B (ja)
HU (1) HU200926B (ja)
IL (1) IL92138A (ja)
IT (1) IT1239542B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JP2964195B2 (ja) * 1992-04-28 1999-10-18 エスエス製薬株式会社 ピロキシカム錠及びその製造法
DE19603402A1 (de) * 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
JP3797387B2 (ja) * 1996-06-14 2006-07-19 協和醗酵工業株式会社 口腔内速崩壊錠
WO1999052491A1 (fr) * 1998-04-08 1999-10-21 Kyowa Hakko Kogyo Co., Ltd. Comprimes et procede de fabrication correspondant
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
PL220457B1 (pl) * 2002-12-16 2015-10-30 Kissei Pharmaceutical Kapsułka do leczenia dysurii
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1920786B8 (en) * 2005-07-25 2012-02-22 Otsuka Pharmaceutical Co., Ltd. Oral preparation for measuring pyrimidine metabolic capacity
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定(fexofenadine)微膠囊及包含其之組合物
WO2014030650A1 (ja) 2012-08-20 2014-02-27 大塚製薬株式会社 糖代謝能の測定方法及びそれに使用する組成物
KR20150132301A (ko) 2013-03-15 2015-11-25 오츠카 세이야쿠 가부시키가이샤 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1308533A (en) * 1969-06-02 1973-02-21 Pfizer Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
US4350689A (en) * 1980-02-15 1982-09-21 American Cyanamid Company Combinations of agents which give enhanced anti-inflammatory activity
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
RO88420A (ro) * 1983-04-25 1986-01-30 Pfizer Inc,Us Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice
DE3419128A1 (de) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen Dihydropyridinpraeparate und verfahren zu ihrer herstellung
CH663899A5 (fr) * 1985-03-20 1988-01-29 Nestle Sa Procede pour la preparation d'une composition a base d'un principe actif de faible hydrosolubilite finement divise.
ES8603754A1 (es) * 1985-07-02 1986-01-01 Ferrer Int Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas

Also Published As

Publication number Publication date
JPH02172918A (ja) 1990-07-04
IT1239542B (it) 1993-11-05
AT399277B (de) 1995-04-25
IT8922164A1 (it) 1991-04-27
GB2224207A (en) 1990-05-02
IL92138A0 (en) 1990-07-12
FR2638357A1 (fr) 1990-05-04
GB8924286D0 (en) 1989-12-13
HU200926B (en) 1990-09-28
GB2224207B (en) 1992-06-10
HUT51143A (en) 1990-04-28
DE3936112A1 (de) 1990-05-31
DE3936112C2 (de) 1999-02-18
FR2638357B1 (fr) 1993-10-22
IT8922164A0 (it) 1989-10-27
CA2001673A1 (en) 1990-04-28
ATA247489A (de) 1994-09-15
IL92138A (en) 1994-08-26

Similar Documents

Publication Publication Date Title
CA2001673C (en) Pharmaceutical composition containing piroxicam
RU2181590C2 (ru) Фармацевтические композиции, содержащие ирбесартан
AU684522B2 (en) Pharmaceutical thermal infusion process
US6143328A (en) Sustained release compositions and a method of preparing pharmaceutical compositions
US5824344A (en) Pharmaceutical thermal infusion granules
TWI415633B (zh) Solid preparations containing enteric solid dispersions
CA2644905A1 (en) Ezetimibe compositions
CZ300558B6 (cs) Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy
EP0365480B1 (en) Dispersible formulation
Bolhuis et al. Evaluation of anhydrous α-lactose, a new excipient in direct compression
IE64659B1 (en) Pimobendan compositions
GB2284760A (en) Sustained release morphine compositions
JPS5927820A (ja) スロクチジルを含有する徐放性製品
US6365196B1 (en) Controlled release solid dosage forms of lithium carbonate
US5827537A (en) Pharmaceutical thermal infusion process
WO1997033571A1 (fr) Preparation d'ecadotril a microdispersion et liberation rapides
JP2002068983A (ja) 8−クロロ−6,11−ジヒドロ−11−(4−ピペリジリデン)−5H−ベンゾ[5,6]シクロヘプタ[1,2−b]ピリジンの経口用組成物
CA1165242A (en) Compressed and formed alkaline component suitable for use in buffered acetylsalicylic acid product
SK279927B6 (sk) Orálne pevné farmaceutické prípravky obsahujúce ge
NO318575B1 (no) Stabile sammensetninger som omfatter levosimendan og alginsyre
US6056974A (en) Rapid-release S1452 tablets
JPH10226644A (ja) 医薬組成物
JP2864737B2 (ja) 徐放性製剤用基剤並びに徐放性製剤及び該製剤の製造方法
WO2023139312A1 (en) Pharmaceutical composition of a cyp11a1 inhibitor
JPH0532554A (ja) 顆粒状カルシウム組成物及びそれからなる錠剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed